ResearcherUniversität UlmNo recent work listed
Andreas Wolfgang Berger
Matched on ORCID iD 0000-0001-9862-7730; OpenAlex author ID A5101510508. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 38
2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper
Papers 7
- Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
- A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
- Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… First author DOI 10.1186/s12885-018-5183-y↗
- Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Co-author DOI 10.18632/oncotarget.23330↗
- Algorithm guided outlining of 105 pancreatic cancer liver metastases in Ultrasound. Co-author DOI 10.1038/s41598-017-12925-z↗
- Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany and review of the literature. Co-author DOI 10.1055/s-0043-105502↗
- DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-016-2052-4↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thomas Jens Ettrich · 6 shared papers, 2016–2022 · strength 0.46
- Paper Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the… DOI 10.1016/j.esmoop.2022.100388↗
- Paper Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. DOI 10.18632/oncotarget.23330↗
- Paper Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany… DOI 10.1055/s-0043-105502↗
- Thomas Theodor Werner Seufferlein · 6 shared papers, 2016–2022 · strength 0.46
- Paper Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the… DOI 10.1016/j.esmoop.2022.100388↗
- Paper Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. DOI 10.18632/oncotarget.23330↗
- Paper Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany… DOI 10.1055/s-0043-105502↗
- Lukas Perkhofer · 3 shared papers, 2016–2018 · strength 0.19
- Paper Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany… DOI 10.1055/s-0043-105502↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Paper DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with ad… DOI 10.1186/s12885-016-2052-4↗
- Michael Geißler · 3 shared papers, 2016–2019 · strength 0.19
- Paper A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. DOI 10.7150/thno.29247↗
- Paper Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONA… DOI 10.1186/s12885-018-5183-y↗
- Paper DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with ad… DOI 10.1186/s12885-016-2052-4↗
- Alexander Kleger · 2 shared papers, 2018–2019 · strength 0.16
- Alexander Hann · 2 shared papers, 2017–2018 · strength 0.16
- Eike Gallmeier · 2 shared papers, 2018–2019 · strength 0.14
- Andrea Tannapfel · 2 shared papers, 2018–2019 · strength 0.14
- Waldemar H. Uhl · 2 shared papers, 2018–2019 · strength 0.14
- Anke Reinacher‐Schick · 2 shared papers, 2018–2019 · strength 0.14
- Alexander Otto König · 2 shared papers, 2018–2019 · strength 0.14
- Hana Algül · 2 shared papers, 2018–2019 · strength 0.14
- Marko Kornmann · 2 shared papers, 2018–2019 · strength 0.14
- Annalena Abendroth · 1 shared paper, 2022 · strength 0.11
- Michael Haas · 1 shared paper, 2022 · strength 0.11
- Steffen Ormanns · 1 shared paper, 2022 · strength 0.11
- Volker Kunzmann · 1 shared paper, 2022 · strength 0.11
- Stephan Krüger · 1 shared paper, 2022 · strength 0.11
- Oliver Waidmann · 1 shared paper, 2022 · strength 0.11
- Sebastian Kobold · 1 shared paper, 2022 · strength 0.11
- Marianne Sinn · 1 shared paper, 2022 · strength 0.11
- Lisa Miller‐Phillips · 1 shared paper, 2022 · strength 0.11
- Volker Heinemann · 1 shared paper, 2022 · strength 0.11
- Jens Thomas Siveke · 1 shared paper, 2022 · strength 0.11
- Jens Werner · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.